The most discussed change in parenteral nutrition compatibility within the last two years was with ceftriaxone. In the summer of 2007, Roche Laboratories updated their prescribing information for Rocephin® (ceftriaxone sodium) to include a contraindication for the co-administration of ceftriaxone with calcium-containing intravenous solutions in neonates due to reported fatal cases of pulmonary and renal precipitates in this patient population.1 The additional warnings to avoid a potential interaction are the most controversial. It is now recommended that ceftriaxone and calcium-containing intravenous solutions, such as parenteral nutrition, not be administered within 48 hours of each other regardless of patient age or remote administration sites. Institutions have struggled with the theoretical expansion of this interaction to older children and adults. At this time, no published case reports could be found in the literature.

Obtaining and maintaining venous access in pediatric patients can be complicated. Many patients require multiple treatment modalities to be administered intravenously including medications, fluids, blood products and nutrition. Clinicians must optimize available access to ensure appropriate and timely administration of all products prior to establishing additional access. Separate administration of intravenous products, if feasible, is always preferred, however, many times simultaneous administration of medications and parenteral nutrition will be required making compatibility considerations essential. It is important to recognize that compatibility only reflects the physical interactions such as formation of a precipitate and does not necessarily address stability or pharmacologic activity of the products. Published data may report both compatibility and stability, however most evaluate visual compatibility alone. Currently there are multiple resources to use when answering the question of compatibility with parenteral nutrition. We strove to evaluate and present the available published data as a comprehensive and practical reference. Primary literature regarding y-site compatibility of medications with three different parenteral nutrition formulas, 3-in-1, 2-in-1 and lipids alone was reviewed. When conflicting results were encountered the clinical strength was considered. When published data was not accessible Trissel's Handbook on Injectable Drugs2 was used.

C

Compatibility has been demonstrated. When Y-site compatibility was not available, medications compatible in solution for 24 hours were assumed to be Y-site compatible. Medications compatible with 3-in-1 admixtures were assumed to be compatible with lipids alone.2 

I

Incompatibility has been demonstrated

Compatibility data not available

C/I

Conflicting compatibility has been demonstrated and strength of the evidence supports compatible

I/C

Conflicting compatibility has been demonstrated and strength of the evidence supports incompatible

1.
Rocephin [package insert]
.
Nutley, NJ
:
Roche Laboratories Inc
;
August 2008
.
2.
Trissel
LA.
Handbook on Injectable Drugs
, 14th ed,
Bethesda, MD
:
American Society of Health-System Pharmacists, Inc
;
2007
.
3.
Veltri
M
,
Lee
CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs
.
Am J Health-Syst Pharm
1996
;
53
:
2611
2613
.
4.
Trissel
LA
,
Gilbert
DL
,
Martinez
JF
,
et al
.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration
.
Am J Health-Syst Pharm
1997
;
54
:
1295
1300
.
5.
Trissel
LA
,
Gilbert
DL
,
Martinez
JF
,
et al
.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures
.
J Parenter Enteral Nut
1999
;
23
:
67
74
.
6.
Mirtallo
JM
,
Caryer
K
,
Schneider
PJ
,
et al
.
Growth of bacteria and fungi in parenteral nutrition solutions containing albumin
.
Am J Hosp Pharm
1981
;
38
:
1907
1910
.
7.
Ambados
F.
Destabilization of fat emulsion in total nutrient admixtures by concentrated albumin 20% infusion
.
Aust J Hosp Pharm
1999
;
29
:
210
212
.
8.
Anderson
PM
,
Rogosheske
JR
,
Ramsey
NKC
,
et al
.
Biological activity of recombinant interleukin-2 in intravenous admixtures containing antibiotic, morphine sulfate or total parenteral nutrition solution
.
Am J Hosp Pharm
1992
;
49
:
608
612
.
9.
Dice
JE.
Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit
.
J Pediatr Pharmacol Ther
2006
;
11
:
233
236
.
10.
Watson
D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solutions
.
J Parenter Enteral Nutr
1985
;
9
:
220
224
.
11.
Schilling
CG.
Compatibility of drugs with a heparin-containing neonatal total parenteral nutrient solution
.
Am J Hosp Pharm
1988
;
45
:
313
314
.
12.
Kamen
BA
,
Gunther
N
,
Sowinsky
N
,
et al
.
Analysis of antibiotic stability in a parenteral nutrition solution
.
Pediatr Infect Dis
1985
;
4
:
387
389
.
13.
Bullock
L
,
Clark
JH
,
Fitzgerald
JF
,
et al
.
The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures
.
J Parenter Enteral Nutr
1989
;
13
:
505
509
.
14.
Andreu
A
,
Cardona
D
,
Pastor
C
,
et al
.
Intravenous aminophylline: in vitro stability of fat-containing TPN
.
Ann Pharmacother
1992
;
26
:
127
128
.
15.
Niemiec
PW
Jr
,
Vanderveen
TW
,
Hohenwarter
MW
,
et al
.
Stability of aminophylline injection in three parenteral nutrient solutions
.
Am J Hosp Pharm
1983
;
40
:
428
432
.
16.
Sykes
R
,
McPherson
C
,
Foulks
K
,
et al
.
Aminophylline compatibility with neonatal total parenteral nutrition
.
J Pediatr Pharmacol Ther
2008
;
13
:
76
79
.
17.
Baptista
RJ
,
Lawrence
RW.
Compatibility of total nutrient admixtures and secondary antibiotic infusions
.
Am J Hosp Pharm
1985
;
42
:
362
363
.
18.
Schuetz
DH
,
King
JC.
Compatibility and stability of electrolytes, vitamins and antibiotics in combination with 8% amino acids solutions
.
Am J Hosp Pharm
1978
;
35
:
33
44
.
19.
Honisko
ME
,
Fink
JM
,
Militello
MA
,
et al
.
Compatibility of argatroban with selected cardiovascular agents
.
Am J Health-Syst Pharm
2004
;
61
:
2415
2418
.
20.
Gilbar
PJ
,
Groves
CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 premix) with selected drugs during simulated Y-site injection
.
Aust J Hosp Pharm
1994
;
24
:
167
170
.
21.
Nahata
MC
,
Zingarelli
J
,
Durrell
DE.
Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions
.
J Clin Pharm Ther
1989
;
14
:
53
55
.
22.
Maxipime [package insert]
.
Princeton, New Jersey
:
Bristol Meyers Squibb Company
;
December 2003
.
23.
Wade
CS
,
Lampasona
V
,
Mullins
RE
,
Parks
RB.
Stability of ceftazidime and amino acids in parenteral nutrient solutions
.
Am J Hosp Pharm
1991
;
48
:
1515
1519
.
24.
Hatton
J
,
Luer
M
,
Hirsch
J
,
et al
.
Histamine receptor antagonists and lipid stability in total nutrient admixtures
.
J Parenter Enteral Nutr
1994
;
18
:
308
312
.
25.
Jacobson
PA
,
Maksym
CJ
,
Landvay
A
,
Weiner
N
,
Whitmore
R.
Compatibility of cyclosporine with fat emulsion
.
Am J Hosp Pharm
1993
;
50
:
687
690
.
26.
Baptista
RJ
,
Dumas
GJ
,
Bistrian
BR
,
et al
.
Compatibility of total nutrient admixtures and secondary cardiovascular medications
.
Am J Hosp Pharm
1985
;
42
:
777
778
.
27.
Ohls
RK
,
Christensen
RD.
Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions
.
Ann Pharmacother
1996
;
30
:
466
468
.
28.
DiStefano
JE
,
Mitrano
JE
,
Baptista
FP
,
et al
.
Long-term stability of famotidine 20 mg/mL in a total parenteral nutrient solution
.
Am J Hosp Pharm
1989
;
46
:
2333
2335
.
29.
Bullock
L
,
Fitzgerald
JF
,
Glick
MR
,
et al
.
Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions
.
Am J Hosp Pharm
1989
;
46
:
2321
2325
.
30.
Bullock
L
,
Fitzgerald
JF
,
Glick
MR.
Stability of famotidine 20 and 50 mg/L in total nutrient admixtures
.
Am J Hosp Pharm
1989
;
46
:
2326
2329
.
31.
Montoro
JB
,
Pou
L
,
Salvador
P
,
et al
.
Stability of famotidine 20 and 40 mg/L in total nutrient admixtures
.
Am J Hosp Pharm
1989
;
46
:
2329
2332
.
32.
Shea
BF
,
Souney
PF.
Stability of famotidine in a 3-in-1 total nutrient admixture
.
DCIP
1990
;
24
:
232
235
.
33.
Moshfeghi
M
,
Ciuffo
J.
Visual compatibility of fentanyl citrate with parenteral nutrient solutions [Letters]
.
Am J Health-Sys Pharm
1998
;
55
:
1194
1197
.
34.
Couch
P
,
Jacobson
P
,
Johnson
CE.
Stability of fluconazole and amino acids in parenteral nutrient solutions
.
Am J Hosp Pharm
1992
;
49
:
1459
1462
.
35.
Chen
MF
,
Boyce
HW
,
Triplett
L.
Stability of the B vitamins in mixed parenteral nutrition solution
.
J Parenter Enteral Nutr
1983
;
7
:
462
464
.
36.
Barker
A
,
Hebron
BS
,
Beck
PR
,
Ellis
B.
Folic acid and total parenteral nutrition
.
J Parenter Enteral Nutr
1984
;
8
:
3
8
.
37.
Louie
N
,
Stennett
DJ.
Stability of folic acid in 25% dextrose, 3.5% amino acids, and multivitamin solution
.
J Parenter Enteral Nutr
1984
;
8
:
421
426
.
38.
Baltz
JK
,
Kennedy
P
,
Minor
JR
,
Gallelli
J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration
.
Am J Hosp Pharm
1990
;
47
:
2075
2077
.
39.
Outman
WR
,
Mitrano
FP
,
Baptista
RJ.
Visual compatibility of ganciclovir sodium and parenteral nutrient solution during simulated Y-site injection
.
Am J Hosp Pharm
1991
;
48
:
1538
1539
.
40.
Johnson
CE
,
Jacobson
PA
,
Chan
E.
Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions
.
Am J Hosp Pharm
1994
;
51
:
503
508
.
41.
Mirtallo
JM
,
Rogers
KR
,
Johnson
JA
,
et al
.
Stability of amino acids and the availability of acid in total parenteral nutrition solutions containing hydrochloric acid
.
Am J Hosp Pharm
1981
;
38
:
1729
1731
.
42.
Holt
RJ
,
Siegert
SWK
,
Krishna
A.
Physical compatibility of ibuprofen lysine injected with selected drugs during simulated Y-site injection
.
J Pediatr Pharmacol Ther
2008
;
13
:
156
161
.
43.
Turowski
RC
,
Durthaler
JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection
.
Am J Hosp Pharm
1991
;
48
:
2181
2184
.
44.
Lindsay
CA
,
Dang
K
,
Adams
JM
,
Ou
CN
,
Baker
CJ.
Stability and activity of intravenous immunoglobulin with neonatal dextrose and total parenteral nutrient solutions
.
Ann Pharmacother
1994
;
28
:
1014
1017
.
45.
Ishisaka
DY
,
VanVleet
J
,
Marquardt
E.
Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion
.
Am J Hosp Pharm
1991
;
48
:
2442
2443
.
46.
Wan
KK
,
Tsallas
G.
Dilute iron dextran formulation for addition to parenteral nutrient solutions
.
Am J Hosp Pharm
1980
;
37
:
206
210
.
47.
Mayhew
SL
,
Quick
MW.
Compatibility of iron dextran with neonatal parenteral nutrient solutions
.
Am J Health-Syst Pharm
1997
;
54
:
570
571
.
48.
Tu
YH
,
Knox
NL
,
Biringer
JM
,
et al
.
Compatibility of iron dextran with total nutrient admixtures
.
Am J Hosp Pharm
1992
;
49
:
2233
2235
.
49.
Vaughan
LM
,
Small
C
,
Plunkett
V.
Incompatibility of iron dextran and a total nutrient admixture
.
Am J Hosp Pharm
1990
;
47
:
1745
1746
.
50.
Athanikar
N
,
Boyer
B
,
Deamer
R
,
et al
.
Visual compatibility of 30 additives with a parenteral nutrient solution
.
Am J Hosp Pharm
1979
;
36
:
511
513
.
51.
Feigin
RD
,
Moss
KS
,
Shackelford
PG.
Antibiotic stability in solutions used for intravenous nutrition and fluid therapy
.
Pediatrics
1973
;
51
:
1016
1026
.
52.
Trissel
LA
,
Williams
KY
,
Gilbert
DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions
.
J Am Pharm Assoc
2000
;
40
:
515
519
.
53.
Pugh
CB
,
Pabis
DJ
,
Rodriguez
C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection
.
Am J Hosp Pharm
1991
;
48
:
123
125
.
54.
Bhatt-Mehta
V
,
Rosen
DA
,
King
RS
,
Maksym
CJ.
Stability of midazolam hydrochloride in parenteral nutrient solutions
.
Am J Hosp Pharm
1993
;
50
:
285
288
.
55.
Akkerman
SR
,
Zhang
H
,
Mullins
RE
,
Yaughn
K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i.v. solutions
.
Am J Health-Syst Pharm
1999
;
56
:
63
68
.
56.
Veltri
MA
,
Conner
KG.
Physical compatibility of milrinone lactate injection with intravenous drugs commonly used in the pediatric intensive care unit
.
Am J Health-Syst Pharm
2002
;
59
:
452
454
.
57.
Bhatt-Mehta
V
,
Paglia
RE
,
Rosen
DA.
Stability of propofol with parenteral nutrient solutions during simulated Y-site injection
.
Am J Health-Syst Pharm
1995
;
52
:
192
196
.
58.
Trissel
LA
,
Bready
BB
,
Kwan
JW
,
Santiago
NM.
Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection
.
Am J Hosp Pharm
1992
;
49
:
402
406
.
59.
Dahl
GB
,
Svensson
L
,
Kinnander
NJ
,
Zander
M
,
Bergstrom
UK.
Stability of multivitamins in soybean oil fat emulsion under conditions simulating intravenous feeding of neonates and children
.
J Parenter Enteral Nutr
1994
;
18
:
234
239
.